Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, José; Campone, Mario; Piccart, Martine; A. Burris, Howard; S. Rugo, Hope; Sahmoud, Tarek; Noguchi, Shinzaburo; Gnant, Michael; I. Pritchard, Kathleen; Lebrun, Fabienne; Thaddeus Beck, J.; Ito, Yoshinori; A. Yardley, Denise; Deleu, Ines; Perez, Alejandra; Bachelot, Thomas; Vittori, Luc; Xu, Zhiying; Mukhopadhyay, Pabak; Lebwohl, David; N. Hortobágyi, Gabriel

doi:10.1056/nejmoa1109653

Public

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Published in New England Journal of Medicine • Dec 7, 2011

Authors:

José Baselga

Mario Campone

Martine Piccart

Abstract

BACKGROUND: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. METHODS: In this phase 3, rand...

Subject

Everolimus

Medicine

PI3K/AKT/mTOR pathway

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!